J&J Ebola vaccine gets 100 million euros to speed development

Your Health Matters

Johnson & Johnson said on Friday that newly formed groups supporting work on its experimental Ebola vaccine would receive 100 million euros ($115 million) from Europe’s Innovative Medicines Initiative to speed development. J&J has been seeking partners after committing up to $200 million to accelerate its Ebola vaccine program in October. The new initiative will see J&J join with institutions including the London School of Hygiene & Tropical Medicine, the University of Oxford and the Institut National de la Sante et de la Recherche Medicale to form consortia working on different aspects of vaccine development. Europe’s Innovative Medicines Initiative (IMI) is a public-private scheme jointly paid for by the European Commission and the pharmaceuticals industry.
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave